• Biotechnology Innovator Specializing in AI Chatbot Solutions for Early Drug Discovery, Infectious Disease and Neurodegenerative Disease Research.
• Strong Progress in Q3 of 2024, Well Positioning CBDW in the AI Chatbot Market.
• Focus on Developing Therapeutic Solutions by Leveraging Human Immune-B Cells for a Cutting-Edge Approach to Highly Effective Treatments.
• Strategic Investment Plan Demonstrating Commitment to Advancing Technological Capabilities and Expanding Reach in the AI Sector.
• Launch of Sutra (TM), a Game-Changing AI Platform for Drug Discovery and Infectious Disease Research.
• Strategic Investment Target Adnexus Biotechnologies Merges with Sanctum Therapeutics for Breakthrough HIV and SARS-CoV-2 Treatments.
• AI Platform Confirmed Decades of Work and Added New Targets for Monoclonal Antibodies with Independent Validation of Their Potential from Collaborators.
• Growing IP Portfolio Including Patents, Trademarks and Trade Secrets.
• Database of 19 Viruses Gives Sutra™ AI Platform Ability to Predict and Help Prevent Future Pandemics.
• Harnessing the Power of AI to Revolutionize Drug Repurposing, Offering a Cost-Effective Alternative to Developing New Drugs from the Ground Up.
1606 Corp. (OTC: CBDW) stands at the forefront of technological innovation, particularly in AI Chatbots. The CBDW mission is to revolutionize customer service, addressing the most significant challenges faced by consumers in the digital marketplace. CBDW is dedicated to transforming the IR industry through cutting-edge AI centric solutions, ensuring a seamless and efficient customer experience.
CBDW is a leading innovator in biotechnology, specializing in AI-driven solutions for early drug discovery, infectious disease, and neurodegenerative disease research. CBDW proprietary methods focus on developing therapeutic solutions by leveraging human immune-B cells, offering a cutting-edge approach to creating highly effective treatments.
CBDW Generative AI Chatbots can provide instant, round-the-clock support, guiding potential investors through the company. Queries about dosage, usage, legality, while offering personalized recommendations based on individual preferences. Moreover, CBDW chatbots can handle multiple interactions simultaneously, ensuring no potential or existing investor feels neglected due to long response times. They also collect valuable data on investor preferences and behaviors, allowing companies to tailor their communication strategies more effectively. In the investor relations industry, where transparency and timely information are paramount, CBDW chatbots can provide up-to-date details on earnings reports, stock performance and company news. This immediate access to information builds confidence with investors, encouraging them to make informed decisions.
The global artificial intelligence market has seen remarkable growth, valued at $428 billion in 2022 and projected to reach $2.25 trillion by 2030. With a compound annual growth rate (CAGR) ranging from 33.2% to 38.1%, AI’s global impact is undeniable, with as many as 97 million individuals expected to work in the AI sector by 2025, according to fortunebusinessinsights.com.
CBDW Highlights Chatbot Capabilities, Adnexus LOI and SEC Reporting Update
On November 19th CBDW announced it has made strong progress in the latest quarter, positioning itself as a key player in the growing AI chatbot market. CBDW has focused on expanding its product offerings, forging strategic partnerships, and investing in innovative AI technology that enhances user interactions across industries. A key milestone for the CBDW Q3 includes strategic partnerships with Adnexus, marking a significant leap in the Company’s AI-driven solutions.
CBDW has filed its 10-Q for the quarter ended September 30, 2024. This filing reflects a commitment to transparency and regulatory compliance, providing investors and shareholders with detailed insights into CBDW financial performance and operational activities.
CBDW made substantial efforts to increase its market reach into the rapidly growing demand for AI-driven customer service and automation tools. CBDW is committed to exploring opportunities for expansion, particularly in sectors such as e-commerce, finance, healthcare, and telecommunications, where AI-powered chatbots are increasingly in demand. CBDW has already created two chatbots that can be tested at www.cbdw.ai.
CBDW signed a Letter of Intent (LOI) with Adnexus Biotechnologies, a leading firm in AI and biotechnology solutions. This potential strategic investment underscores the CBDW commitment to expanding its technological footprint and enhancing its capabilities in the rapidly evolving field of AI. CBDW management believes the integration of Adnexus’s cutting-edge AI research and development expertise would significantly bolster its portfolio, bringing advanced solutions to the intersection of artificial intelligence and healthcare and biotech.
Looking ahead, CBDW focus will be on:
Closing the investment in Adnexus Biotechnologies.
CBDW will continue to enhance its AI capabilities, with plans to launch additional AI-powered chatbot solutions that offer businesses even more advanced tools for automation, customer service, and engagement.
Through the partnership with Adnexus, CBDW aims to expand its reach into new verticals, such as healthcare, finance, and telecommunications, where AI chatbots are rapidly becoming essential for operational efficiency.
As AI solutions like Chat IR gain traction, CBDW expects to see a rise in demand for its products, which can contribute to revenue growth in the next quarters.
CBDW Investment Targer Adnexus Biotechnologies Merges with Sanctum Therapeutics to Obtain Breakthrough HIV and SARS-CoV-2 Treatments
On November 12th CBDW acquisition target Adnexus Biotechnologies Inc. revealed completion of a merger agreement to acquire Sanctum Therapeutics core technology assets for treating HIV and SARS-CoV-2. This merger will combine the two biotechnology companies’ significant resources and expertise.
Adnexus Biotechnologies is poised to revolutionize its HIV and infectious disease portfolio with the acquisition of Sanctum Therapeutics’ leading-edge assets. This strategic merger combines Adnexus’s state-of-the-art AI-driven drug discovery platform with Sanctum’s innovative long-acting HIV capsid inhibitor and Adnexus’s short-acting anti-HIV monoclonal antibodies.
The acquisition further strengthens the CBDW position in the rapidly growing market for HIV treatments, while also expanding its pipeline of drug candidates targeting antimicrobial-resistant infections and other infectious diseases.
Unveils Sutra (TM) is a Game-Changing AI Platform for Drug Discovery and Infectious Disease Research
On October 1st CBDW announced its new AI Empowered Drug Discovery Platform, Sutra™.
The CBDW Sutra™ AI platform has not just confirmed decades of work, but also added new targets for monoclonal antibodies within weeks, receiving independent validation of their potential from collaborators. CBDW AI algorithms have identified several promising drug candidates. CBDW has identified a target in the mitochondrial metabolism that has a role in oncology. CBDW then adds them to an ever-growing IP portfolio, including patents, trademarks, and trade secrets, enhancing its competitive advantage and potential for future revenue. The success and validation of the CBDW Sutra™ AI platform for AI-discovered drugs are testaments to its capabilities and the future it promises.
Using CBDW AI-powered structure prediction algorithms, this platform has the potential to revolutionize drug discovery. It can design small molecules, optimize the design of antibodies and other proteins, and even repurpose drug molecules.
With a database of 19 viruses, the CBDW Sutra™ AI platform can predict and help prevent future pandemics. Having access to a curated library of 8 million molecules, the CBDW platform makes possible the discovery of new drugs that precisely target neutralizable epitopes on viruses to enhance the potency and efficacy of existing therapies. The CBDW Sutra™ team’s unwavering dedication to leveraging microbiome samples to identify new biomarkers for neurodegenerative diseases instills hope for future medical breakthroughs.
CBDW harnesses the power of AI to revolutionize drug repurposing, offering a cost-effective alternative to developing new drugs from the ground up. Drug repurposing involves identifying potential new applications for existing compounds, which can be time-consuming and labor-intensive. However, AI algorithms can analyze existing drug databases and identify potential new applications for these compounds in a fraction of the time, making it a game-changer in the pharmaceutical industry. CBDW is exploring synergizing AI with suitable linkers between antibodies and drugs to promote multi-drug combinations. This approach will bring new therapeutics to market with more substantial impacts than combination therapies and address unmet medical needs, expediting drug discovery and regulatory approvals.
For more information on $CBDW visit: www.cbdw.ai and https://www.adnexusbiotech.com
Disclaimer and Disclosure: www.aibrandnetwork.com
Media ContactCompany Name: 1606 Corp.Contact Person: Austen Lambrecht, CEOEmail: Send EmailPhone: (602) 481-1544Address:2425 East Camelback Road Suite 150 City: PhoenixState: AZ 8501Country: United StatesWebsite: https://www.adnexusbiotech.com
